Maintaining Momentum in the Treatment of Chronic Idiopathic Constipation: Framing Practical Clinical Strategies Through Case Studies


Michael Camilleri, MD
Professor of Medicine, Pharmacology, and Physiology, Mayo Clinic, Rochester, MN
Atherton and Winifred Bean Professor of Medicine, Pharmacology, and Physiology
Mayo Clinic, Rochester, MN
Michael Camilleri, MD
Professor of Medicine, Pharmacology, and Physiology, Mayo Clinic, Rochester, MN

Dr. Camilleri is a consultant in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, Minnesota, and is Professor of Medicine, Pharmacology, and Physiology at Mayo Clinic College of Medicine and Science. His research interests include clinical enteric neurosciences, gut neurohormonal control, obesity, irritable bowel syndrome, and pharmacology and pharmacogenomics; his work is funded by National Institutes of Health. He has received numerous awards and honors including the 2012 Ismar Boas Medal from the German Society of Digestive and Metabolic Disease, the 2012 American Gastroenterological Association (AGA) Distinguished Mentor Award, the Janssen Research Award, the AGA Joseph B. Kirsner Award, the AGA Julius Friedenwald Medal in 2021, as well as honorary doctorates from the University of Antwerp (Belgium) and the University of Malta, and he was elected to the membership of the prestigious Association of American Physicians. Dr. Camilleri participates in educational and mentorship activities at Mayo Clinic and has mentored more than 80 national and international postdoctoral fellows and scientists. He maintains an active clinical practice in gastroenterology at Mayo Clinic, specializing in gastrointestinal motility disorders, gastroparesis, and functional GI disorders. He is Past-President of the American Neurogastroenterology and Motility Society and the American Gastroenterological Association as well as former editor of Clinical Gastroenterology and Hepatology and Neurogastroenterology and Motility.

Lucinda A. Harris, MS, MD, FACG, AGAF, FACP
Associate Professor of Medicine, Scottsdale, AZ
Associate Professor of Medicine
Consultant, Division of Gastroenterology and Hepatology
Mayo Clinic - Alix School of Medicine
Scottsdale, AZ
Lucinda A. Harris, MS, MD, FACG, AGAF, FACP
Associate Professor of Medicine, Scottsdale, AZ

Lucinda A. Harris, MS, MD, is currently Associate Professor of Medicine, Mayo Clinic Alix School of Medicine and Consultant, Division of Gastroenterology and Hepatology, Mayo Clinic Scottsdale. She graduated from the University of Connecticut School of Medicine. She completed her Internal Medicine Residency at the New York Presbyterian Hospital of Columbia University and her fellowship in Gastroenterology & Hepatology at The New York Hospital /Weill Medical College of Cornell University. She was on the faculty in the Division of Gastroenterology & Hepatology at Weill Cornell Medical School before moving to her current position at Mayo Clinic.

At the Mayo Clinic she has been a past Co-Director of the Motility Group and has led a patient support group there for IBS. Dr. Harris is a current member of the Gastroenterology Fellowship committee and serves as the Department Education coordinator for Gastroenterology, supervising visiting GI fellows and medical students. She has actively been involved in mentoring medical students, residents, and fellows over the years.

Professionally, Dr. Harris is currently President of the Phoenix GI Society. She is also active in professional organizations as a Fellow of the American College of Gastroenterology, the American Gastroenterological Association, and the American College of Internal Medicine. She is also a member of the American Neurogastroenterology and Motility Society. Her special clinical and research interests are in IBS, gastroparesis, chronic constipation, and pelvic floor disorders as well as celiac disease and autonomic disorders. Dr. Harris has written and lectured extensively on these topics.

Professor of Clinical Gastroenterology, University of Texas Health Science Center, Houston, TX

Dr. Cash is Chief of the Division of Gastroenterology, Hepatology, and Nutrition at the University of Texas Health Science Center at Houston, where he is also the Dan and Lillie Sterling Professor of Clinical Gastroenterology at the University of Texas McGovern Medical School and the Endowed Director of the Chao-Ertan Directorship at Memorial Hermann Hospital Texas Medical Center. Dr. Cash received his undergraduate degree in Business Administration (Finance) with Honors from the University of Texas in Austin and earned his medical degree from the Uniformed Services University of Health Sciences in Bethesda, MD. He completed his internship, residency, and gastroenterology fellowship at the National Naval Medical Center in Bethesda, MD, and served for 24 years in the United States Navy, retiring in 2014. Dr. Cash has authored over 200 articles and book chapters on a wide variety of gastrointestinal topics and his clinical interests include disorders of brain-gut interaction, colorectal cancer screening, artificial intelligence, and Barrett esophagus. He was recognized as one of the best gastroenterologists in Houston by Houstonia magazine in 2019 and a Top Doctor by Texas Monthly magazine in 2020 and 2021. In 2020 he was named a Rome Foundation Fellow and was recently appointed to the Rome V Functional Bowel Disorders Committee.

Statement of Need

Despite its prevalence, chronic idiopathic constipation (CIC) is often underdiagnosed, undertreated, and mismanaged, exacting a significant personal and economic burden for affected individuals. Overlapping symptoms with other functional gastrointestinal disorders complicate the diagnosis and treatment of CIC. There is a need for practical strategies in choosing and interpreting appropriate diagnostic tests, as well as a thorough understanding of safety and efficacy data in order to efficiently and effectively progress through the treatment continuum.

In this CME Outfitters OnDemand symposium, expert faculty will frame the CIC decision tree with patient cases in order to achieve a confident diagnosis, implement effective treatment plans to improve outcomes, and improve quality of life for patients with CIC.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Accurately diagnose CIC, differentiating it from IBS-C.
  • Evaluate the characteristics of therapies used in the management of CIC.
  • Develop a comprehensive treatment strategy for patients with CIC, constructed from evidence and clinical guidelines.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in gastroenterology and/or primary care

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 1.5

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

California Residents

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE) 1.5

This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy credit. Jump to Activity UAN.
Activity UAN: 0376-0000-21-062-H02-P

Nurses (ANCC) 1.5

This activity is designated for 1.5 contact hours. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Camilleri reports the following financial relationships: Consultant: Acadia Pharmaceuticals Inc.; Aditum Bio; AEON Biopharm; BioKier, Inc.; Colospan; Cosma Pharmaceuticals; Fauna Bio; Novome Biotechnologies, Inc.; Pfizer Inc.; Protagonist Therapeutics, Inc.; QED Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; and Zealand Pharma A/S. Grants: NGM Biopharmaceuticals and Vanda Pharmaceuticals. Other financial or material support: option to receive stock for consulting with Bilayer Therapeutics; Dignify Therapeutics; Enterin Inc.; and Thelium Therapeutics

Dr. Cash reports the following financial relationships: Advisory Board: AbbVie Inc.; Phathom Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc. Consultant: Alexion; Motus; Nestle; and Phathom Pharmaceuticals. Research Support: Napo Pharmaceuticals, Inc. Speakers Bureau: AbbVie Inc.; Alnylam Pharmaceuticals, Inc; QOL Medical, LLC; RedHill Biopharma Ltd; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Harris reports the following financial relationships: Consultant: AbbVie (formerly Allergan); Alnylam Pharmaceuticals, Inc.; Gemelli Biotech; GI Health Foundation; Ironwood Pharmaceuticals, Inc.; Rome Foundation; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc. (formally Shire). Research Support: Allakos Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
  • Susan Perry (planning committee)
  • Kasey Brandt, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.


Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Maintaining Momentum in the Treatment of Chronic Idiopathic Constipation: Framing Practical Clinical Strategies Through Case Studies
Event Date: 06/02/2022